# The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis

Study · id `cardio:ct-nct04981327` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04981327](<https://clinicaltrials.gov/study/NCT04981327>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04981327

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1300 participants.

## Technical summary

Registry record NCT04981327. Randomized; single masking; primary purpose treatment. Start 2022-09-01 (anticipated); primary completion 2026-08-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1300 participants (planned count; ClinicalTrials.gov record NCT04981327, source copy `cardio:ctgov-nct04981327-2021-07-29`, retrieved 2026-10-31)
- Planned start: 2022-09-01 (anticipated) (ClinicalTrials.gov record NCT04981327, source copy `cardio:ctgov-nct04981327-2021-07-29`, retrieved 2026-10-31)
- Primary completion: 2026-08-31 (anticipated) (ClinicalTrials.gov record NCT04981327, source copy `cardio:ctgov-nct04981327-2021-07-29`, retrieved 2026-10-31)
- Completion: 2027-08-31 (anticipated) (ClinicalTrials.gov record NCT04981327, source copy `cardio:ctgov-nct04981327-2021-07-29`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04981327-2021-07-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
- Acronym: API-CALF
- Condition: Deep Vein Thrombosis
- Intervention (Drug): Apixaban 2.5 MG Oral Tablet \[ELIQUIS\]
- Lead sponsor: University Hospital, Geneva
- Lead sponsor class: OTHER
- Collaborator: Sunnybrook Health Sciences Centre
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Apixaban (Eliquis) (`cardio:eliquis`)
- Registry intervention name is a brand that an FDA record in the corpus ties to this substance: Apixaban (`cardio:apixaban`)
- Registry lists this organization as the lead sponsor: University Hospital, Geneva (`cardio:org-university-hospital-geneva`)
- Registry lists this organization as a collaborator: Sunnybrook Health Sciences Centre (`cardio:org-sunnybrook-health-sciences-centre`)

## Provenance

Content hash: 06723d8fb023b36753a682b09195e02cd248817179c76a6894815d65dfaa9d46
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
